Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2

Nature Medicine
B AgrawalB M Longenecker

Abstract

A number of adenocarcinomas abundantly express and secrete underglycosylated MUC1 mucin. Underglycosylation exposes tandem repeat peptide sequences on cancer-associated MUC1 mucin that are normally cryptic. High levels of MUC1 mucin are correlated with a poor prognosis and immunosuppression in adenocarcinoma patients. In this report we show that cancer-associated MUC1 mucin, affinity-purified from ascites fluids of cancer patients, and synthetic tandem repeats of MUC1 mucin core peptide can suppress human T-cell proliferative responses. This MUC1 mucin-induced suppression of T-cell responses can be reversed by the addition of exogenous IL-2 or anti-CD28 monoclonal antibody. These results are consistent with other studies showing that lymphocytes present in the vicinity of tumor cells are anergic and can be reactivated with exogenous interleukin-2. Overcoming MUC1 mucin-induced immunosuppression with IL-2 combined with active specific immunotherapy might be an effective immunotherapeutic strategy against human adenocarcinomas.

References

Jun 1, 1992·International Immunology·B BeverlyR H Schwartz
Jan 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H KobayashiY Kawashima
Sep 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·S J GendlerJ Taylor-Papadimitriou
Apr 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·J SiddiquiD Kufe
Apr 1, 1995·Human Pathology·M A McGuckinR G Wright
Mar 23, 1995·Cancer Letters·J HilkensC Patriarca
Jan 1, 1995·Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy·R B AlexanderS A Rosenberg
Jan 1, 1994·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A BerrutiL Dogliotti
Jul 1, 1996·Immunobiology·H MayumiK Nomoto
Nov 1, 1996·Science·M Barinaga
Jun 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D W ChanM Evelegh

❮ Previous
Next ❯

Citations

Jun 17, 1998·International Journal of Cancer. Journal International Du Cancer·M ReddishB M Longenecker
Jul 27, 1999·International Journal of Cancer. Journal International Du Cancer·A K ChanP S Goedegebuure
May 3, 2005·Cancer Immunology, Immunotherapy : CII·J WiereckyP Brossart
Feb 3, 2005·Virchows Archiv : an International Journal of Pathology·Claudio SorioAldo Scarpa
Mar 30, 2002·Molecular Immunology·Fernando J IrazoquiGustavo A Nores
Dec 22, 1999·Journal of Hepatology·S M CruickshankL K Trejdosiewicz
Nov 26, 1999·Biochimica Et Biophysica Acta·J Taylor-PapadimitriouM Dalziel
Nov 2, 1999·Micron : the International Research and Review Journal for Microscopy·J R Harris, J Markl
Sep 22, 2001·Biomolecular Engineering·D T O'HaganM Singh
Jun 9, 2000·Breast Cancer Research and Treatment·D ChenJ Gong
Jan 5, 2002·Breast Cancer Research and Treatment·M V CroceA Segal-Eiras
Sep 20, 2001·Breast Cancer Research and Treatment·J M HansonJ P Pearson
Oct 15, 1998·Nature Medicine·V A BoussiotisL M Nadler
Mar 21, 1998·Nature Medicine·A N Houghton, K O Lloyd
Nov 6, 2007·Cancer Biotherapy & Radiopharmaceuticals·Zheng LiJie Ma
Dec 14, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L DecosterJ F Vansteenkiste
Sep 29, 2011·The Cancer Journal·Ronan J Kelly, Giuseppe Giaccone
Feb 15, 2000·American Journal of Respiratory and Critical Care Medicine·Y HirasawaM Miyake
Jul 17, 2001·Biochemical and Biophysical Research Communications·K HandaS I Hakomori
Dec 1, 2006·Annual Review of Immunology·Gabriel A RabinovichEduardo M Sotomayor
Jan 5, 2002·Proceedings of the National Academy of Sciences of the United States of America·Sen-itiroh Hakomori Si
Jun 5, 2002·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M GionE Marubini
Jun 30, 2009·Cancer Immunology, Immunotherapy : CII·Miriam ReuschenbachNicolas Wentzensen
May 3, 2014·Journal of Cancer Research and Clinical Oncology·Ya-Wen WangPeng Gao
Dec 30, 2006·Cancer Immunology, Immunotherapy : CII·Eirikur SaelandYvette van Kooyk
Jul 20, 2010·Immunotherapy·Richard E BeatsonJoy M Burchell
Apr 9, 2011·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Håkan MellstedtNick Thatcher
Feb 18, 2006·Cancer Immunology, Immunotherapy : CII·Antje DanielczykSteffen Goletz
Sep 4, 2012·Cancer Immunology, Immunotherapy : CII·Lixin ZhangOlivera J Finn
Jul 20, 2005·Expert Review of Vaccines·Scott North, Charles Butts
Dec 22, 2006·Expert Review of Vaccines·Miriam E Mossoba, Jeffrey A Medin
Dec 22, 2006·Expert Review of Anticancer Therapy·Simon J HarrisonH Miles Prince
Oct 18, 2011·Expert Review of Anticancer Therapy·Cesar A PerezLuis E Raez
Dec 28, 2011·Expert Review of Endocrinology & Metabolism·Pamela E ConstantinouDaniel D Carson

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.